BCRX - BioCryst Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
7.13
-0.03 (-0.42%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close7.16
Open7.17
Bid0.00 x 900
Ask0.00 x 1000
Day's Range6.86 - 7.24
52 Week Range4.12 - 8.13
Volume489,989
Avg. Volume646,887
Market Cap781.405M
Beta (3Y Monthly)2.06
PE Ratio (TTM)N/A
EPS (TTM)-0.83
Earnings DateNov 5, 2018 - Nov 9, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.25
Trade prices are not sourced from all markets
  • GlobeNewswire7 days ago

    Analysis: Positioning to Benefit within Ardelyx, AXT, TG Therapeutics, MarineMax, Oclaro, and BioCryst Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK, Oct. 16, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Grifols (GRFS) Surges: Stock Moves 5.4% Higher
    Zacks11 days ago

    Grifols (GRFS) Surges: Stock Moves 5.4% Higher

    Grifols (GRFS) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

  • GlobeNewswire27 days ago

    BioCryst Pharmaceuticals to Present at the Cantor Fitzgerald Global Healthcare Conference

    RESEARCH TRIANGLE PARK, N.C., Sept. 25, 2018 -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the company will present at the Cantor Fitzgerald Global.

  • GlobeNewswirelast month

    BioCryst Receives Additional $3.5 Million to Fund Clinical Trials of Galidesivir in Yellow Fever

    BioCryst Pharmaceuticals, Inc. (BCRX) today announced that the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded BioCryst an additional $3.5 million to support clinical trials of galidesivir in patients with yellow fever. Yellow fever represents a significant unmet medical need and a new potential use of galidesivir. With this additional $3.5 million contract amendment, the NIAID development contract for galidesivir now totals $43.0 million.

  • What Sarepta Therapeutics’ Valuation Trend Indicates
    Market Realistlast month

    What Sarepta Therapeutics’ Valuation Trend Indicates

    Sarepta Therapeutics (SRPT) incurred a net loss of $109.27 million in the second quarter of 2018 compared to a net loss of $63.05 million in Q2 2017. Its net loss per share was $1.15 in the second quarter of 2017. Despite the surge in revenues, Sarepta’s net loss widened due to higher operating expenses, which increased from $98.35 million in the second quarter of 2017 to $176.96 million in the second quarter of 2018.

  • Here's Why BioCryst Pharmaceuticals Rose 21.3% in August
    Motley Foollast month

    Here's Why BioCryst Pharmaceuticals Rose 21.3% in August

    Believe it or not, share prices rose after the company announced a share offering.

  • GlobeNewswire2 months ago

    CDC Awards BioCryst $35 Million RAPIVAB® Contract for Strategic National Stockpile

    BioCryst Pharmaceuticals, Inc. (BCRX), a pharmaceutical company focused on the development and commercialization of treatments for rare diseases, today announced that the Centers for Disease Control and Prevention (CDC) has awarded BioCryst a $34.7 million contract for the procurement of up to 50,000 doses of BioCryst’s approved antiviral influenza therapy, RAPIVAB® (peramivir injection) over a five-year period. The CDC’s purchase of RAPIVAB will supply the Strategic National Stockpile, the nation’s largest supply of potentially life-saving pharmaceuticals and medical supplies for use in a public health emergency. “We appreciate the CDC acknowledging the value of RAPIVAB to patients and our national security,” said Jon Stonehouse, chief executive officer of BioCryst.

  • GlobeNewswire2 months ago

    CORRECTION -- BioCryst Reports Positive Results Across Multiple Endpoints in ZENITH-1 Trial of Oral BCX7353 as Acute Therapy for Hereditary Angioedema (HAE) Attacks

    In a release issued under the same headline earlier today by BioCryst Pharmaceuticals, Inc. (BCRX), please note that in the first line of the table, the values for the change from baseline in VAS score through 4 hours under BCX7353 Treated Attacks and Placebo Treated Attacks are numbers, not percentages as previously published. Please also note a footnote has been added to the end of the table within the release, which notes baseline composite VAS scores for both BCX7353 treated attacks and placebo treated attacks. RESEARCH TRIANGLE PARK, N.C., Sept. 04, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (BCRX) today announced initial results from the ZENITH-1 trial showing that a single 750 mg oral dose of BCX7353 was well tolerated and superior to placebo (p

  • GlobeNewswire2 months ago

    BioCryst Reports Positive Results Across Multiple Endpoints in ZENITH-1 Trial of Oral BCX7353 as Acute Therapy for Hereditary Angioedema (HAE) Attacks

    BioCryst Pharmaceuticals, Inc. (BCRX) today announced initial results from the ZENITH-1 trial showing that a single 750 mg oral dose of BCX7353 was well tolerated and superior to placebo (p

  • GlobeNewswire2 months ago

    BioCryst Pharmaceuticals to Present at the Baird Global Healthcare Conference

    RESEARCH TRIANGLE PARK, N.C., Aug. 29, 2018-- BioCryst Pharmaceuticals, Inc. today announced that the company will present at the Baird Global Healthcare Conference in New York on Thursday, September 6, ...

  • GlobeNewswire2 months ago

    New Research Coverage Highlights Cincinnati Bell, BioCryst Pharmaceuticals, Shutterstock, Kopin, Lands' End, and Pieris Pharmaceuticals — Consolidated Revenues, Company Growth, and Expectations for 2018

    NEW YORK, Aug. 15, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Cincinnati ...

  • BioCryst Pharmaceuticals (BCRX) Reports Q2 Loss, Tops Revenue Estimates
    Zacks3 months ago

    BioCryst Pharmaceuticals (BCRX) Reports Q2 Loss, Tops Revenue Estimates

    BioCryst (BCRX) delivered earnings and revenue surprises of 17.39% and 228.79%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire3 months ago

    BioCryst Reports Second Quarter 2018 Financial Results

    RESEARCH TRIANGLE PARK, N.C., Aug. 07, 2018-- BioCryst Pharmaceuticals, Inc. announced today financial results for the second quarter ended June 30, 2018.. “Building on the clear direction from our shareholders ...

  • GlobeNewswire3 months ago

    BioCryst Pharmaceuticals Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares and Completion of Public Offering of Common Stock

    BioCryst Pharmaceuticals, Inc. (BCRX) announced today the completion of an underwritten public offering of 10,454,546 shares of its common stock, including 1,363,636 shares sold pursuant to the exercise in full of the underwriters’ option to purchase additional shares. The gross proceeds from this offering to BioCryst, including from the shares sold pursuant to the underwriters’ option to purchase additional shares, were approximately $57.5 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by BioCryst.

  • GlobeNewswire3 months ago

    U.S. FDA Grants Fast Track Designation for BioCryst’s BCX7353

    BioCryst Pharmaceuticals, Inc. (BCRX), a pharmaceutical company focused on the development and commercialization of treatments for rare diseases, today announced that the Company has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) for BCX7353 for the prevention of angioedema attacks in patients with hereditary angioedema (HAE). Fast Track Designation provides opportunities for frequent interactions with the FDA during development of a product candidate and provides the opportunity for priority review if supported by clinical data at the time of the new drug application (NDA) submission.

  • Why BioCryst Pharmaceuticals Stock Is Bolting Higher Today
    Motley Fool3 months ago

    Why BioCryst Pharmaceuticals Stock Is Bolting Higher Today

    Investors are cheering the orphan drug specialist's decision to raise a nice chunk of capital via a public offering.

  • GlobeNewswire3 months ago

    BioCryst Pharmaceuticals Prices Public Offering of Common Stock

    BioCryst Pharmaceuticals, Inc. (BCRX) announced today the pricing of an underwritten public offering of 9,090,910 shares of its common stock, offered at a price to the public of $5.50 per share.  The gross proceeds from this offering to BioCryst are expected to be $50 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by BioCryst.  BioCryst has granted the underwriters a 30-day option to purchase up to an additional 1,363,636 shares of its common stock.  The offering is expected to close on or about August 6, 2018, subject to customary closing conditions.

  • GlobeNewswire3 months ago

    BioCryst Pharmaceuticals Commences Public Offering of Common Stock

    BioCryst Pharmaceuticals, Inc. (BCRX) a biotechnology company focused on the development and commercialization of treatments for rare and infectious diseases, announced today that it is offering to sell $50 million of its common stock in an underwritten public offering. As part of this offering, BioCryst intends to grant the underwriters a 30-day option to purchase up to an additional $7.5 million of its common stock. J.P. Morgan and Jefferies are acting as joint book-running managers for the proposed offering.

  • GlobeNewswire3 months ago

    BioCryst to Announce Second Quarter 2018 Financial Results on August 7

    RESEARCH TRIANGLE PARK, N.C., July 27, 2018-- BioCryst Pharmaceuticals, Inc. announced today that its second quarter 2018 financial results will be reported on Tuesday, August 7, 2018.. BioCryst will host ...

  • GlobeNewswire3 months ago

    BioCryst Announces Publication of APeX-1 Clinical Trial Results for BCX7353 in The New England Journal of Medicine

    BioCryst Pharmaceuticals, Inc. (BCRX), a pharmaceutical company focused on the development and commercialization of treatments for rare diseases, today announced that results from the Phase 2, APeX-1 clinical trial of BCX7353 for the prevention of attacks in patients with hereditary angioedema (“HAE”) are published online in the July 26th issue of The New England Journal of Medicine (DOI: 10.1056/NEJMoa1716995). The trial demonstrated that oral administration of BCX7353 at a dose of 125 mg or more resulted in a significantly lower rate of attacks compared with placebo. Mild gastrointestinal symptoms were the principal side effect, particularly in the 250 mg and 350 mg BCX7353 dose groups.

  • ACCESSWIRE3 months ago

    Stock Performance Review on AVEO Pharma and Three Other Biotech Stocks

    LONDON, UK / ACCESSWIRE / July 24, 2018 / If you want a free Stock Review on AVEO sign up now at www.wallstequities.com/registration. All you have to do is sign up today for this free limited time offer by clicking the link below.

  • Why American Airlines, Idera Pharmaceuticals, and RH Holdings Slumped Today
    Motley Fool3 months ago

    Why American Airlines, Idera Pharmaceuticals, and RH Holdings Slumped Today

    From a scuttled merger to tariff troubles, see why shares of these three companies fell hard today.

  • Why Idera Pharmaceuticals Is Sinking Today
    Motley Fool3 months ago

    Why Idera Pharmaceuticals Is Sinking Today

    Shares plunge after its proposed merger is called off. Here's what investors need to know.

  • Business Wire3 months ago

    BioCryst Provides Update on Strategy, Pipeline and Outlook

    BioCryst Pharmaceuticals, Inc. (BCRX) (“BioCryst” or the “Company”), a pharmaceutical company focused on the development and commercialization of treatments for rare diseases, today provided an update on the Company’s strategic and financial outlook as a standalone company following the recent termination of its merger agreement with Idera Pharmaceuticals, Inc. (IDRA) (“Idera”). Jon P. Stonehouse, President and Chief Executive Officer of BioCryst, said, “We are moving forward executing our standalone strategy with a great deal of confidence in our programs, our pipeline and our ability to drive value for our stockholders. Also, we are on track for a first half of 2019 initiation of a Phase 1 clinical trial for our ALK-2 inhibitor program for treating fibrodysplasia ossificans progressiva, or FOP.